PERTH, Australia – Most multinational pharma companies vehemently opposed the Therapeutic Goods Administration's plan to stick with the status quo in Australia and use a single name for biologics and biosimilars without a specific identifier suffix. Even so, the regulator said it would continue to use its single naming system and beef up its adverse event reporting system.
PERTH, Australia – Most multinational pharma companies vehemently opposed the Therapeutic Goods Administration's plan to stick with the status quo in Australia and use a single name for biologics and biosimilars without a specific identifier suffix. Even so, the regulator said it would continue to use its single naming system and beef up its adverse event reporting system.
PERTH, Australia – Australia’s Viralytics Ltd. is on its way to completing its phase Ib immunotherapy programs of lead candidate Cavatak following a A$29.6 million (US$23.9 million) private placement earlier this month with China’s Lepu Medical Group.
PERTH, Australia – Australia's Imugene Ltd. could be the first biotech out of the gate in developing B-cell peptide vaccines in the immune-oncology space.
PERTH, Australia – Australia's Imugene Ltd. could be the first biotech out of the gate in developing B-cell peptide vaccines in the immune-oncology space.
PERTH, Australia – A Senate inquiry on research funding models for cancers with low survival rates has returned a report that outlines 25 recommendations to improve infrastructure, clinical trials and reimbursement processes for cancer drugs in Australia.
PERTH, Australia – Unlike its Australian peers, regenerative medicine company Regeneus Ltd. is not focusing on the U.S. market. Instead, it's placing its bets on Japan first and then will move out to other territories.
PERTH, Australia – A Senate inquiry on research funding models for cancers with low survival rates has returned a report that outlines 25 recommendations to improve infrastructure, clinical trials and reimbursement processes for cancer drugs in Australia.
